Safety immunological response recombinant vaccinia virus vaccine HIV envelope glycoprotein randomised phase trial recombinant vaccina virus vaccine envelope gene human immunodeficiency virus healthy HIV-seronegative males history smallpox immunisation vaccinia naive weeks standard NY strain vaccinia virus frequency duration titre virus isolation vaccination site occurrence local side-effects similar groups vaccinees Vaccinia-naive vac-n subjects virus vaccination site titre vaccinia-primed vac-p individuals days vs pfu/ml In-vitro T-cell proliferative responses HIV antigen preparations vaccinia-primed subjects T-cell responses transient subject antibodies HIV detectable vaccinia-naive subjects strong T-cell responses homologous heterologous strains whole virus protein detectable year antibodies HIV envelope Recombinant vaccinia virus vaccines T-cell priming foreign gene products individuals sole immunising agent efficacious vaccinia-naive individuals 